We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

75 hedge funds and large institutions have $119M invested in Stemline Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

104% more call options, than puts

Call options by funds: $2.41M | Put options by funds: $1.18M

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

14% more capital invested

Capital invested by funds: $104M → $119M (+$14.7M)

1% more funds holding

Funds holding: 74 → 75 (+1)

Holders
75
Holders Change
+1
Holders Change %
+1.35%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
33
Reduced
15
Closed
14
Calls
$2.41M
Puts
$1.18M
Net Calls
+$1.23M
Net Calls Change
+$881K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.69M
3
FCM
Farallon Capital Management
California
+$8.29M
4
Axa
Axa
France
+$3.96M
5
IBT
International Biotechnology Trust
United Kingdom
+$3.01M

Top Sellers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
-$2.61M
2
Invesco
Invesco
Georgia
-$1.81M
3
BIM
Bogle Investment Management
Massachusetts
-$1.01M
4
VMI
VHCP Management II
New York
-$801K
5
Renaissance Technologies
Renaissance Technologies
New York
-$701K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$21.7M +$9.69M +1,063,457 +72%
Franklin Resources
2
Franklin Resources
California
$12.4M – – –
BlackRock
3
BlackRock
New York
$10.4M +$11M +1,211,309 +33,798%
FCM
4
Farallon Capital Management
California
$9.98M +$8.29M +910,000 +353%
EAM
5
Eventide Asset Management
Massachusetts
$9.29M +$2.14M +235,000 +28%
Vanguard Group
6
Vanguard Group
Pennsylvania
$7.05M +$1.86M +204,228 +33%
BBA
7
Baker Bros. Advisors
New York
$5.42M +$2.73M +300,000 +90%
Axa
8
Axa
France
$3.71M +$3.96M +434,183 New
Millennium Management
9
Millennium Management
New York
$3.66M +$2.41M +263,921 +161%
IBT
10
International Biotechnology Trust
United Kingdom
$2.81M +$3.01M +330,000 New
State Street
11
State Street
Massachusetts
$2.65M +$533K +58,443 +23%
SFM
12
Sphera Funds Management
Israel
$2.56M +$2.73M +300,000 New
SM
13
Sabby Management
Florida
$2.48M -$617K -67,719 -19%
Northern Trust
14
Northern Trust
Illinois
$1.99M +$265K +29,095 +14%
VMI
15
VHCP Management II
New York
$1.95M -$801K -87,850 -28%
GTC
16
Ghost Tree Capital
New York
$1.92M +$2.05M +225,000 New
CCI
17
Columbus Circle Investors
$1.84M +$1.07M +117,187 +120%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.37M +$246K +27,029 +20%
JGC
19
J. Goldman & Co
New York
$1.2M -$546K -59,886 -30%
B
20
Bailard
California
$1.19M +$137K +15,000 +12%
Deutsche Bank
21
Deutsche Bank
Germany
$1.02M -$472K -51,798 -30%
AG
22
Artal Group
Luxembourg
$855K +$911K +100,000 New
PAM
23
Panagora Asset Management
Massachusetts
$840K +$390K +42,777 +77%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$745K +$210K +23,077 +36%
CI
25
Cowen Inc
New York
$657K +$701K +76,900 New
1
2 3 4

STML Hedge Fund Activity: Q1 2017 in Review

75 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2017, worth a combined $119M — up 14% from $104M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new STML positions and 14 closed out — a net gain of 6 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $11M. The largest seller was Candriam SCA, exiting entirely with an estimated $2.61M sold.

  • 75 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2017, up from 74 in Q4 2016.
  • Funds reported $119M of Stemline Therapeutics, Inc. stock for Q1 2017, up 14% quarter-over-quarter.
  • 20 funds opened new Stemline Therapeutics, Inc. positions in Q1 2017 and 14 closed out, a net change of +6 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $11M added.
  • The largest Stemline Therapeutics, Inc. seller in Q1 2017 was Candriam SCA, an estimated $2.61M sold.

Based on aggregated 13F filings for Q1 2017.